Member Info for Lancygeo

http://www.watoday.com.au/world/blue-diamond-may-be-a-world-beater-20140614-zs812.html? Blue diamond may be a world beater The 122.52 carat blue diamond. Photo: Petra Diamonds An "exceptional" 122-carat blue diamond, which could be one of the most valuable found, has been unearthed at a South African mine. The diamond was discovered in the Cullinan mine near Pretoria - the same location where some of the gems in the Crown jewels were found. It is expected to sell for more than £20 million ($36 million) but will be worth a lot more when it is cut, and could break current records. Recently, the Pink Star, a 59.6-carat cut pink diamond, fetched £49 million when it was sold at auction. Petra chief executive Johan Dippenaar holding the 122.52 carat blue diamond. Photo: Petra Diamonds The highest price recorded for a rough diamond was £20 million, in February 2010, for a 507-carat white stone, also recovered from Cullinan. "We think that this stone may break that record," said Martin Potts, of analyst FinnCap. Petra Diamonds, the London-listed firm that acquired the Cullinan mine in 2008, said tests were still needed on the "exceptional stone" to determine its value. The company confirmed it would not be sold before June 30. A spokesman for Petra said: "The rarity of a blue diamond of this magnitude sets it apart as a truly significant find." Blue stones are rarer, and much more valuable than their white counterparts. The world's largest certified diamond - the 3106-carat Cullinan - was found at the mine in 1905. It was cut to form the Great Star of Africa and the Lesser Star of Africa, set in the Crown jewels. Telegraph, London

.........fasten your belts. :)

http://www.connectingindustry.com/ElectricalEngineering/dialight-releases-first-atexiecex-led-streetlight-with-7-year-warranty-improved-safety-reliability.aspx Dialight releases first ATEX/IECEx LED streetlight with 7 year warranty, improved safety & reliability 10 June 2014 New Third-Party certified StreetSense® fitting is designed using ATEX/IECEx Ex nA protection method to meet and exceed the needs of electrical engineers seeking roadway and area lighting for Zone 2 hazardous areas Dialight (LSE: DIA.L), the global leader in LED lighting technology, has unveiled its latest innovation in LED hazardous area lighting. With options of 10,900 lumens (131W) and 20,250 lumens (252W), Dialight’s new StreetSense® LED fitting carries a seven-year full performance warranty and provides excellent quality of light for facility roadways in oil, gas, chemical, petrochemical, pharmaceutical and other hazardous applications.

first off some massive sells...........and now some massive buys? any ideas anyone?

...positivity :)

.....of possitivity ! ...........here we go :)

http://www.thestreet.com/story/12708152/1/emeralds-and-rubies-and-amethysts-oh-my-a-talk-with-gemfields-ian-harebottle.html? Emeralds and Rubies and Amethysts, Oh My: A Talk with Gemfields' Ian Harebottle As those watching the diamond space are no doubt aware, colored diamonds are becoming increasingly popular, with the best specimens fetching incredibly high prices at auction as investors and celebrities alike snap them up. With all that attention directed at diamonds, it can be easy to forget that they're by no means the only type of colored gemstone out there. However, not everyone is content to let diamonds steal the spotlight. Ian Harebottle, CEO of Gemfields (LSE:GEM), the world's largest producer of colored gemstones, is one such person. To find out more about the market for colored gemstones like rubies, emeralds and amethysts, Diamond Investing News (DIN) got in touch with Harebottle. In the interview below, he explains why colored gemstones are making a comeback, also touching on what qualities to look for in such stones and where they are found. In closing, he gives his opinion on whether colored gemstones can be considered an investment. DIN: One of the things that prompted me to get in touch with you was a recent Mining Weekly article that says Gemfields is "doing for emeralds what De Beers did for diamonds." What exactly does that mean? IH: Until about the 1940s, global colored gemstone sales were pretty much on par with diamond sales, but then a shift began to arise within the luxury goods value proposition, moving away from the primary drivers of rarity, beauty and quality towards the importance of marketing and branding. De Beers focused not only on the mining and supplying of diamonds to the world, but also on marketing, branding and positioning, with campaigns such as "diamonds are forever," "diamonds are a girl's best friend" and so on. It's one thing to supply rare gemstones, but it's another to help consumers understand the importance, the rarity and the value that are inherent within these gems as opposed to all of the other luxury goods on offer.

Once the initial results from the soft launch are made public I expect it will be rolled out across the board. I reckon the financial savings to the NHS by introducing 'Dermapure' to market for the treatment for leg ulcers alone will be colossal. This is just the beginning.

......to read about the 'Soft launch' of DermaPure. Does anyone know any more about this, which hospitals etc?

http://www.proactiveinvestors.co.uk/companies/news/68619/tissue-regenix-poised-for-us-launch-68619.html? Tissue Regenix poised for US launch Tissue Regenix is a company that focuses on delivering practical solutions to real clinical issues using its patented dCELL® process. The dCELL® Process removes foreign cells & DNA and provides a matrix that repopulates with patients own cells once its implanted - integrating into the patients own tissues. Regenerative medical devices company Tissue Regenix (LON:TRX) remains on course to launch its DermaPure flagship product Stateside in the first half of the year. The company added in its full-year results that the ‘soft launch’ of DermaPure in the UK by the National Health Service Blood and Transplant (NHBST) authority has gone well, with initial positive results from patients and clinicians. The company spent much of 2013 gearing up for the commercialisation phase of its evolution, with a particular emphasis on the US. The group made an operating loss of £6.6mln in the 12 months to the end of January, having made a loss the year before of £4.4mln. The heavier losses were in line with management expectations and reflect the anticipated acceleration of the use of cash as the group progresses its development programme and pre-clinical and clinical trials. Loss after tax widened to £5.6mln from £3.5mln the year before. The company expects to get a tax refund this year of around £710,000. The group ended the reporting period with a healthy cash balance of £18.5mln, down from £24.2mln the year before. "This year, we have continued to invest in our product development programme and are poised to deliver a scalable commercial roll-out of products using our dCELL technology. We have made a lot of progress in a relatively short space of time, particularly in the US, where we are now in a strong position to capitalise on opportunities in what is the world's largest healthcare market," said Anthony Odell, Tissue Regenix’s chief executive officer. The statement from chairman John Samuel said the company is working with leading health economic consultancy to develop the case for using the company’s constructs and its growing body of current and future clinical data. “We foresee this work highlighting the tangible social and economic benefits of using our dCELL technology platform,” Samuel said. The proprietary platform technology, dCELL, is used to decellularise human or animal donor tissue to create biological scaffolds that are then implanted into patients to replace diseased or damaged parts of their body. “Regenerative medicine holds great future promise for the long term treatment of many medical problems. We are close to delivering the first of our products to market in a format that makes adoption by clinicians and hospitals simple and economically attractive,” he cla

well done........you said we were due a bounce.

..........news well overdue. RNS due any time now.

http://www.dailymail.co.uk/health/article-2269810/Me-operation-Glue-patch-help-heal-chronic-leg-ulcers.html Just stumbled across this old article from January. Thought I'd read just about everything about TRX and leg ulcers but missed this one. Whether you're in the know or not this link serves as a great reminder as to what TRX is all about.

Not sure whether a sales team will be required......hoping the clinical trials and successful launch in the US will be the catalyst for the future. "NHSBT have the UK rights and are planning to launch product but have not released a date yet." Target for me is still a quid :)

by my reckoning........due within the next 10 days.

Possibly, but still in Q1 so news might be on its way soon :)

http://www.thegrocer.co.uk/companies/conviviality-retail-kicks-off-franchisee-reward-scheme/355403.article?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=rss

http://www.proactiveinvestors.co.uk/companies/news/66650/gemfields-attention-turns-to-rubies-ahead-of-auction-66650.html Gemfields’ attention turns to rubies ahead of auction By Jamie Nimmo March 13 2014, 12:18pm City firm Canaccord Genuity thinks the auction will be a good yardstick for ruby pricing and will shed more light on Montepuez’s value Fans of Gemfields (LON:GEM) will be keeping a close eye on the coloured gemstone group’s first ruby auction due in June. The AIM-listed company recently started developing its next producing asset, the 75%-owned Montepuez ruby mine in Mozambique, following the success of its Kagem emerald mine in Zambia. City firm Canaccord Genuity thinks the auction will be a good yardstick for ruby pricing and will shed more light on the project’s value. “We do not think this auction will represent the true demand and pricing, but it should provide clarity on general pricing scales and allow us to better model the operation,” said analyst Dmitry Kalachev. He thinks Montepuez will be the near-term catalyst for investors. The analyst, who currently has a 40p target price, expects to be able to include the mine in his valuation once pricing and the development plan become clearer. He has an early-stage valuation of 16p a share for the ruby project. Kalachev lifts his valuation on Kagem by 19% to 32p a share (unrisked) on the assumption of a longer mine life (following the decision to push back the pit wall), as well as higher pricing. His valuation of Fabergé however falls 30% to 10p a share due to lower sales growth forecasts. The shares are currently trading at 36p.

...the SP is due for a run out. £ 2 next stop.

topped up.